drugset / Trial / NCT03144687
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in participants with myelofibrosis (MF).
Timeline
- Start
- 2018-01-26
- Primary completion
- 2020-03-14
- Completion
- 2021-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itacitinib | Small molecule | 200 mg | Oral |
| Subject | Itacitinib | Small molecule | 600 mg | Oral |
| Background | Ruxolitinib | Small molecule | — | Oral |